March 3, 2022Open Access

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

LCLi ChenFujian Medical University YJYi‐Zhou JiangNanjing Agricultural University SWSong‐Yang WuShanghai Medical College of Fudan University

Key Points

Key points are not available for this paper at this time.

Abstract

The triplet regimen was efficacious and well tolerated in previously untreated, advanced, immunomodulatory TNBC. The randomized controlled FUTURE-SUPER trial is under way to validate our findings. See related commentary by Salgado and Loi, p. 2728.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Chen et al. (Thu,) studied this question.

synapsesocial.com/papers/69daae36a6045d71bfa3dbd3 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-21-4313

Demander à l'IA

Bookmark

View Full Paper